A Study to Evaluate the Effect of Cimetidine on CD4 Lymphocyte Counts in HIV Infection
Completed
Community Research Initiative of New England
N/A
1969-12-31
To determine the change in CD4 count after 4 and 8 weeks in HIV-infected patients treated
with cimetidine compared to placebo. To observe time-associated trends at weeks 4, 8, 12, and
16 in the change of CD4 counts for patients taking cimetidine for the full 16 weeks. To
establish a safety record for cimetidine use in HIV-positive patients.
Biological Therapy in Treating Patients With Metastatic Cancer
Completed
Hoag Memorial Hospital Presbyterian
Phase 2
1996-01-01
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop
cancer cells from growing. Combining different types of biological therapies, including
interferon alfa, interleukin-2, and tumor infiltrating lymphocytes, may kill more cancer
cells.
PURPOSE: Phase II trial to study the effectiveness of biological therapies, including
interferon alfa, interleukin-2, and tumor infiltrating lymphocytes, in treating patients with
metastatic cancer.
Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer
Completed
Genentech, Inc.
Phase 3
2001-04-01
The purpose of this study is to evaluate the addition of Herceptin to standard chemotherapy
treatment of patients newly diagnosed with operable breast cancer.
Other objectives: 1) to evaluate the potential of this therapy to reduce the size of the
tumor and increase the possibility of breast conservative surgery, 2) evaluate the ability of
this regimen to prevent recurrence of breast cancer and impact on survival, 3) determine side
effect profile with the addition of Herceptin, and 4) evaluate significance of HER2
expression by two different methods.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
